Drug · DIN 02230713
LIPITOR
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since August 2, 2023; first marketed March 5, 1997.
- Drug Identification Number (DIN)
- 02230713
- Company (DIN owner)
- BGP Pharma ULCEtobicoke, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Atorvastatin C10AA05
- Class
- Human
- Record last updated
- August 21, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| ATORVASTATIN (ATORVASTATIN CALCIUM) | 20 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- August 2, 2023: NOC 31358New Drug Submission (NDS) · Administrative: Change in Product Ownership
- May 1, 2020: NOC 23543New Drug Submission (NDS) · Change in product ownership
- January 24, 2001: NOC 1697New Drug Submission (NDS) · Manufacturer name change
- February 19, 1997: NOC 3289New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “lipitor”. A notice may cover another product or only some lots: read it to see what it covers.
- Archive -Counterfeit lipitor found again in the United KingdomAugust 2, 2006 · Drugs
Other DINs named LIPITOR
- DIN 02230711 · Marketed
- DIN 02230714 · Marketed
- DIN 02243097 · Marketed